Substance abuse and pharmacy practice: what the community pharmacist needs to know about drug abuse and dependence
Tóm tắt
Pharmacists, the most accessible of health care professionals, are well positioned to help prevent and treat substance use disorders and should prepare themselves to perform these functions. New research improves our knowledge about the pharmacological and behavioral risks of drug abuse, supports the clinical impression that drug dependence is associated with long-lasting neurochemical changes, and demonstrates effective pharmacological treatments for certain kinds of drug dependencies. The profession is evolving. Pharmacists are engaging in new practice behaviors such as helping patients manage their disease states. Collaborative practice agreements and new federal policies set the stage for pharmacists to assist in the clinical management of opioid and other drug dependencies. Pharmacists need to be well informed about issues related to addiction and prepared not only to screen, assess, and refer individual cases and to collaborate with physicians caring for chemically dependent patients, but also to be agents of change in their communities in the fight against drug abuse. At the end of this article the pharmacist will be better able to:
Tài liệu tham khảo
Haack MR, Hoover A: Strategic Plan for Interdisciplinary Faculty Development: Arming the Nation's Health Professional Workforce for a New Approach to Substance Use Disorders. Substance Abuse. 2002, 23 (3): 1-21.
Dole EJ, Tommasello A: Recommendations for Implementing Effective Substance Abuse Education in Pharmacy Practice. Substance Abuse. 2002, 23 (3): 263-271.
Leshner AI: Addiction is a Brain Disease and It Matters. Science. 1997, 278 (5335): 45-47. 10.1126/science.278.5335.45.
Miller WR, Walters ST, Bennett ME: How effective is alcoholism treatment in the United States?. J Stud Alcohol. 2001, 62: 211-220.
O'Malley PM, Johnston LD, Bachman JG: Adolescent Substance Abuse Epidemiology and Implications for Public Policy. Pediatric Clinics of North America. 1995, 42 (2): 241-260.
Dabney DA: Onset of Illegal use of Mind-Altering or Potentially Addictive Prescription Among Pharmacists. Journal of the American Pharmaceutical Association. 2001, 41 (2): 392-400.
The Children's Health Act of 2000 Title 35, Section 3501 the Drug Addiction Treatment Act of 2000. H.R. 4365 of the 106th Congress, January 2000.
Smith DE, Seymour R: A Clinical Approach to the Impaired Health Professional. Int J Addict. 1985, 20 (7): 13-22.
American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders. Washington D.C., American Psychiatric Association. 1994, 4
Grant BF, Dawson DA: Alcohol and Drug Use, Abuse, and Dependence: Classification, Prevalence, and Comorbidity. in Addictions A Comprehensive Guidebook. Edited by: McCrady BS, Epstein EE. 1999, Oxford University Press, Chapter 1:
Hyman SE: Initiation and Adaptation: A Paradigm for Understanding Psychotropic Drug Action. American Journal of Psychiatry. 1996, 153: 151-162.
Schuckit MA: Biological Vulnerability to Alcoholism. J Consult Clin Psychol. 1987, 55 (30): 1-9.
Grant BF, Peterson LA, Dawson DS, Chou SP: Source and accuracy statement for the National Longitudinal Alcohol Epidemiological Survey. Rockville, MD. National Institute on Alcohol Abuse and Alcoholism. 1994
Anthony JC, Warner LA, Kessler RC: Comparative epidemiology of dependence on tobacco, alcohol, controlled substances, and inhalants: Basic findings from the National Comorbidity Survey. Exp Clin Psychopharmacol. 1994, 2: 244-268. 10.1037//1064-1297.2.3.244.
Rosenberg MF, Anthony JC: Early manifestations of cannabis dependence in a community sample. Drug and Alcohol Dependence. 2001, 64: 123-131. 10.1016/S0376-8716(00)00229-5.
McGinnis J, Michael F, William H: Actual Causes of Death in the United States. JAMA. 1993, 270 (18): 2207-2212. 10.1001/jama.270.18.2207.
ASHP position statement on pharmaceutical care. Am J Hosp Pharm. 1993, 50: 1720-1723.
Conlan MF: APhA forges ahead with mission statement for all of pharmacy. Drug Topics. 1991, 135: 74-75.
Fiore MC, Bailey WC, Cohen SJ: Treating Tobacco Use and Dependence. Clinical Practice Guideline. Rockville, Md.: U.S. Department of Health and Human Services. Public Health Service. 2000
Smith MD, McGhan WF, Lauger G: Pharmacist counseling and outcomes of smoking cessation. American Pharmacy. 1995, NS35 (8): 20-9.
Benowitz NL: Nicotine addiction. Primary Care Clinics in Office Practice. 1999, 26 (3): 611-31.
Hansten PD, Horn JR: Drug Interactions: Analysis and Management. Applied Therapeutics Vancouver, WA. 2001, (updated regularly)
Mistry SK, Sorrentino AP: Patient Non-adherence: The $100 Billion Problem. American Druggist. 1999, 216: 56-63.
Lucas GM, Cheever LW, Chaisson RE, Moore RD: Detrimental Effects of Continuous Illicit Drug Use on the Treatment of HIV-1 Infection. Journal of Acquired Immune Deficiency Syndromes. 2001, 27 (3): 251-259.
Ewing JA: Detecting Alcoholism: The CAGE questionnaire. JAMA. 1984, 252: 1905-1907. 10.1001/jama.252.14.1905.
Brown RL, Leonard T: A Two Item Conjoint Screen for Alcohol and Other Drug Problems. Journal of the American Board of Family Practice. 2001, 14: 95-106.
Williams R, Vinson DC: Validation of a Single Screening Question for Problem Drinking. Journal of Family Practice. 2001, 50 (4): 307-320.
Johnson RE, Strain EC, Amass L: Buprenorphine: How to use it right. Drug and Alcohol Dependence. 2003, 70: S59-S77. 10.1016/S0376-8716(03)00060-7.
O'Farrell TJ, Fals-Stewart W: Treatment Models and Methods: Family Models. Addictions A Comprehensive Guidebook. Edited by: McCrady BS, Epstein EE. 1999, Oxford University Press, Chapter 16:
Chassin L, Curran PJ, Hussong AM, Colder CR: The Relation of Parent Alcoholism to Adolescent Substance Use: A Longitudinal Follow-UP Study. Journal of Abnormal Psychology. 1996, 105 (1): 70-80. 10.1037//0021-843X.105.1.70.
Sanjuan PM, Langenbucher JW: Age-Limited Populations: Youth, Adolescents, and Older Adults. Addictions A Comprehensive Guidebook. Edited by: McCrady BS, Epstein EE. 1999, Oxford University Press, Chapter 16:
Knight JR, Shrier LA: A new brief screen for adolescent substance abuse. Arch Pediatr Adolesc Med. 1999, 153: 591-596.
Tommasello AC: The Pharmacology of Alcohol and Street Drugs in the Context of Trauma Care. Trauma Quarterly. 2000, 14 (4): 365-384. 10.1163/156857100750225088.
Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, Gibson D, Mandelbaum A, Etlinger A, Mechoulam R: Isolation and Structure of a Brain Constituent that Binds to the Cannabinoid Receptor. Science. 1992, 258: 1946-1949.
Aghajanian GK: Serotonin and the Action of LSD in the Brain. Psychiatric Annals. 1994, 24 (3): 137-141.
Cedarbaum JM, Aghajanian GK: Activation of locus coeruleus neurons by peripheral stimuli: modulation by a collateral inhibitory mechanism. Life Sciences. 1978, 23: 1383-1391. 10.1016/0024-3205(78)90398-3.
McCabe OL: Psychedelic Drug Crisis: Toxicity & Therapeutics. J Psychedelic (Psychoactive) Drugs. 1977, 9 (2): 107-121.
Nicholson KL, Balster RL: GHB: a new and novel drug of abuse. Drug and Alcohol Dependence. 2001, 63: 1-22. 10.1016/S0376-8716(00)00191-5.
Morgan MJ: Ecstasy (MDMA): A Review of its Possible Persistent Psychological Effects. Psychopharmacology. 2000, 152: 230-248. 10.1007/s002130000545.
Green RA, Cross AJ, Goodwin GM: Review of the pharmacology and clinical pharmacology of 2,3-methylenedioxymethamine (MDMA or Ecstasy). Psychopharmacology. 1995, 119: 247-260.
Chang L, Grob CS, Ernst T, Itti L, Mishkin FS, Jose-Melchor R, Poland RE: Effect of Ecstasy [3,4-methylenedioxymethamphetamine (MDMA)] on Cerebral Blood Flow: A co-registered SPECT and MRI Study. Psychiatry Research Neuroimaging. 2000, 98: 15-28. 10.1016/S0925-4927(99)00048-7.
McCann UD, Szabo Z, Scheffel U, Dannals RF, Ricaurte GA: Positron Emission Tomographic Evidence of Toxic Effects of MDMA (Ecstasy) on Brain Neurons in Human Beings. Lancet. 1998, 352: 1433-1437. 10.1016/S0140-6736(98)04329-3.
Chang L, Ernst T, Grob CS, Poland R: Cerebral 1H MRS Alterations in Recreational 3,4,-methylenedioxymethamphetamine (MDMA, "Ecstasy") Users. Journal of Magnetic Resonance Imaging. 1999, 10: 521-526. 10.1002/(SICI)1522-2586(199910)10:4<521::AID-JMRI4>3.3.CO;2-0.
Chang L, Grob CS, Ernst T, Itti L, Mishkin FS, Jose-Melchor R, Poland RE: Effect of Ecstasy [3,4-methylenedioxymethamphetamine (MDMA)] on Cerebral Blood Flow: A co-registered SPECT and MRI Study. Psychiatry Research Neuroimaging. 2000, 98: 15-28. 10.1016/S0925-4927(99)00048-7.
Prochaska JO: Changing for Good. 1994, New York, William Morrow
Miller WR, Rollnick S: Motivational Interviewing: Preparing People to Change Addictive Behavior. 1991, New York, Guilford Press
Levinson W, Cohen MS, Brady D, Duffy DF: To Change or Not To Change: "Sounds Like You Have a Dilemma.". Annals of Internal Medicine. 2001, 135 (5): 386-391.
Roman PM: The Use of EAPs in Dealing With Drug Abuse in the Workplace. NIDA Research Monograph #91. 1989, 271-286.
Penna RP, Williams RL: Helping the Impaired Pharmacist – A Handbook for Planning and Implementing State Programs American Pharmaceutical Association. Washington, D.C. 1985
Trinkoff AM, Storr C: Relationship of Specialty and Access to Substance Use Among Registered Nurses: An Exploratory Analysis. Drug and Alcohol Dependence. 1994, 36: 215-219. 10.1016/0376-8716(94)90147-3.
Blazer LK, Mansfield PK: A Comparison of Substance Use Rates Among Female Nurses, Clerical Workers and Blue Collar Workers. Journal of Advanced Nursing. 1995, 21 (2): 305-313.
Tommasello AC: The Effects of State Policies on Addiction Intervention in the Health Professions: The Case of Pharmacy. Dissertation, University of Maryland. 2000